Minerva Neurosciences announced its third quarter 2026 financial results and business updates, highlighting progress in its Phase 3 trial of roluperidone, a drug targeting negative symptoms of schizophrenia. The ongoing C19 study aims to confirm prior positive results, with topline efficacy data expected in the second half of 2027. The company reported increased R&D and administrative expenses due to trial activities, a GAAP net income of $100.7 million driven by a non-cash gain on warrant liabilities, and a cash position of $77 million as of September 30, 2026. Minerva also plans a key opinion leader event on November 12, 2026, to discuss roluperidone's potential.
Minerva Neurosciences' third quarter 2026 financial results and business updates come amid a Health sector where 51 of 150 US stocks rose and 94 fell on Pluang. For readers following Health stocks, here is Pluang's market snapshot as of Nov 06, 2026 20:42 WIB: Amphastar Pharmaceuticals Inc (AMPH) rose 6.47% to USD 29.45 with a typical hold time of 18 days, Cassava Sciences Inc (FLNA) gained 6.21% to USD 0.48 with 79% buy order activity and a 39-day hold time, and Erasca Inc. (ERAS) increased 3.77% to USD 13.77 with a typical hold time of 4 days.
BriaCell Therapeutics and its subsidiary BriaPro presented positive preclinical data at the SITC 2026 Annual Meeting, highlighting their immunotherapy platforms Bria-OTS+ and BP-80. Bria-OTS+ showed broad immune activation and sustained cancer cell k...
IMUNON, Inc. presented new data from its Phase 2 OVATION 2 trial showing that IMNN-001, combined with chemotherapy, significantly enhances anti-tumor T-cell immune responses in advanced ovarian cancer patients. This immune activation correlates with ...
Canary Capital has launched the Canary Staked INJ ETF (INJC) on Nasdaq, providing investors exposure to INJ, the native token of the Injective blockchain. The ETF not only tracks INJ's price but also earns staking rewards from the network's proof-of-...
The Ozempic market, valued at $30.04 billion in 2026, is projected to grow to $113.95 billion by 2032, with a CAGR of 24.89%. This growth is fueled by increasing demand for diabetes and metabolic health treatments, wider adoption of GLP-1 therapies, ...
Nexans has signed a subcontract to deliver a 420 km mass-impregnated 110 kV cable system for the 1 GW, 320 kV Corinth-Kos HVDC interconnection in Greece. This project, awarded to Hellenic Cables and partners, will connect the Dodecanese islands to ma...
